Results 241 to 250 of about 66,892 (264)

Loss of ELF2 drives topotecan resistance in retinoblastoma revealed by genome-wide CRISPR-Cas9 screening. [PDF]

Cell Death Dis
Jiang J, Jiang Z, Luo Q, Chen X, Zhuang J, Chen J, Mu Q, Qiu J, Li Y, Chen S, Zhang P, Yu K, Chen S, Liu GS, Zhuang J.   +14 more
europepmc   +1 more source

Mitochondrial Calcium Uniporter Drives Chemoresistance in Pancreatic Cancer via Glutathione‐Mediated Stemness Maintenance

Advanced Science, EarlyView.
PDAC has a poor prognosis due to chemoresistance. We revealed that MCU upregulation is associated with chemoresistance and stemness in PDAC. MCU‐mediated Ca2+ influx induced ER stress, activating the PERK‐ATF4/NRF2 axis to enhance PSAT1/SLC711 expression and glutathione synthesis, reducing ROS and maintaining stemness.
Zekun Li, Chenyang Meng, Guangcong Shen, Yueying Shan, Junjin Wang, Diliyaer Abudukeremu, Rui Zhao, Bo Ni, Chao Xu, Xiaofan Guo, Jun Yu, Kaiyuan Wang, Shengyu Yang, YunZhan Li, Yongjie Xie, Tianxing Zhou, Jihui Hao, Xiuchao Wang   +17 more
wiley   +1 more source

Metformin glycyrrhetinic acid binary injectable hydrogel for synergistic tumor immunotherapy via spatiotemporal microenvironment remodeling. [PDF]

Mater Today Bio
Ouyang A, Qin X, Su B, Mo S, Jiang J, Wang Z, Li Y, Lu J, Lin Y, Wang J, Fan L, Jin R.   +11 more
europepmc   +1 more source

Regulating Tumor Metabolic Reprogramming with Biomimetic Co‐Delivery of Simvastatin and Kynureninase for Immunotherapy

Advanced Science, EarlyView.
After the intravenous injection of biomimetic and pH/ROS‐responsive PTSK@CRM, the nanoparticles can be accumulated in tumors and release Sim and KYNase to inhibit the tumor growth, regulate the metabolism of cholesterol and Kyn, and reverse the immunosuppressive tumor microenvironment.
Jiaxin Yin, Shengcai Yang, Zengguang Liu, Songchen Zhao, Siyu Sun, Ziling Liu, Quanshun Li   +6 more
wiley   +1 more source

Sorafenib nanomedicine in HCC: nano-bio interactions and combination therapies. [PDF]

J Nanobiotechnology
Lu T, Zhu W, Lin C, Zhang Z, Lim LHK, Cui J.   +5 more
europepmc   +1 more source

Three‐Year Follow‐Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer‐Associated Fibroblast Heterogeneity Corresponding to PD‐1 Blockade Efficacy

Advanced Science, EarlyView.
Heterogeneous cancer‐associated fibroblasts orchestrate dual immune microenvironments in LAGC. Abstract The potential for immunotherapy in patients with locally advanced gastric cancer (LAGC) is recently confirmed. To report the 3‐year follow‐up data are aimed from a novel clinical trial. This is a prospective single‐arm phase II trial.
Yao Lin, Xiong Sun, Chengguo Li, Ming Yang, Ke Wu, Ke Liu, Anshu Li, Xiaoming Shuai, Kailin Cai, Zheng Wang, Guobin Wang, Peng Zhang, Jianfeng Shen, Kaixiong Tao, Yuping Yin   +14 more
wiley   +1 more source

Fosinopril mediates antitumor efficacy by inducing GSDME-dependent pyroptosis in NSCLC. [PDF]

Cell Death Discov
Gao Y, Zhai X, Zhang C, Zhao H, Ji B, Sun R, Du X, Du Y, Gao S, Zhang Y, Wang T.   +10 more
europepmc   +1 more source

Unveiling the therapeutic potential of silibinin in head and neck squamous cell carcinoma via network pharmacology. [PDF]

Sci Rep
Zheng Y, Xia Y, Ling J, Zhao H, Zhuo X.
europepmc   +1 more source

Immune suppression in MTAP-deficient cancers via glutamate metabolism and CXCL10 downregulation. [PDF]

Front Immunol
Chang WH, Zhang J, Hong QS, Chen CH.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Innovations in research and clinical care using patient‐generated health data

Ca-A Cancer Journal for Clinicians, 2020
H S L Jim, Aasha I Hoogland, Naomi C Brownstein   +2 more
exaly